Www.clinicalmicrobiologyandinfection.com

Humanized pharmacokinetic profiles were generated in vitro by targeting a given terminal half-life (2 h for meropenem and 8 h for polymyxin B) while maintaining the fAUC 24 for each drug, as done in previous studies.[3-5] Polymyxin B exhibits biphasic kinetics in humans, however logistical constraints in the in vitro system dictate the use of a one compartment model for pharmacokinetics. ................
................